

S (MART) Therapies for Asthma

Holger Link, MD

Disclosures and Conflict of Interest

None

Objectives

- Discuss asthma phenotypes and specific therapies
- Review current recommendations in updated National Asthma Education and Prevention Program and GINA guidelines
- Review S(MART) therapy for asthma

What is asthma?

NHLBI 2007


“a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role: in particular, mast cells, eosinophils, T lymphocytes, macrophages, neutrophils, and epithelial cells. In susceptible individuals, this inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. These episodes are usually associated with widespread but variable airflow obstruction that is often reversible either spontaneously or with treatment. The inflammation also causes an associated increase in the existing bronchial hyperresponsiveness to a variety of stimuli. Reversibility of airflow limitation may be incomplete in some patients with asthma” (10).

What is asthma?


GINA 2019


“a heterogenous disease, usually characterized by **chronic airway inflammation** defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness, and cough that vary over time and in intensity, together with variable expiratory airflow limitations.”

Normal Airway





Asthma












Type-2 High Asthma


Eos
Mucus
Mast cells
FeNo



Type-2 Low Asthma

Neutrophils
Obesity
Metabolic dysfunction
No T2 markers

"Type-2 Asthma"



Mild CS responsive early onset allergic asthma

Mediators: IL-4, 13, IgE

Rx: ICS

Early onset, moderate-severe CS treated-modestly responsive allergic asthma

Mediators: IL-4, 13, IL-5, IgE

Rx: CSs, Anti-IgE/anti-IL4R

Late onset eosinophilic Moderate-severe/less CS responsive Nasal polyposis

Mediators: IL-4, 5, 13, leukotrienes


Rx: CSs, Anti IL-4R/Anti-IL-5/5R

Complex T2 Very severe, T cell/Type-1 dominant autoimmunity

Mediators: IL-4,5,13 IFN γ

Rx: Anti-IL4R/Anti-IL-5/5R with/without alternative immunosuppressive

Type-2-Low "Asthma"



Stable mild asthma
Intermittent obstruction

Mediators: mast cell related?

Rx:
bronchodilators/low dose ICS?

Late onset obese
airway disease
minimal obstruction and reversibility

Mediators: IL-6, IL-1 β

Rx: weight loss/metabolic targets, Anti-IL-6?

Early onset,
long disease duration
high dose CS Rx
moderate obstruction/minimal BD response

Mediators: unknown

Rx:
unclear/thermoplasty?

Late onset,
infection/smoking
Sputum production/moderate obstruction


Mediators:
Neutrophilic/inflammasome

Rx: macrolides?, anti-IL-1 β ? Mucus clearance measures

Objectives

Review current recommendations in updated National Asthma Education and Prevention Program and GINA guidelines

Once upon a time....



Asthma Guidelines

- National Asthma Education And Prevention Program (NAEPP)
- Global Initiative for asthma (GINA)

National Asthma Education And Prevention Program

NAEPP

- Started 1989
 - Federal Program
- Initial Guideline 1991
- Revisions
 - 1997, 2002, 2007, and 2020

Global Initiative for Asthma

GINA

- Launched 1993:
 - National Heart, Lung and Blood Institute
 - National Institutes of Health
 - World Health Organization
- Since 2014 funded entirely by the sale of its documents and resources.
- Guidelines updated annually!

How to use the Guidelines?

“The diagrams are intended to help clinicians integrate the new recommendations into clinical care, and are meant to assist, and not replace, clinical judgment or decision-making for individual patient management, with input from individuals with asthma about their preferences”

What are the Benefits?

- Standardization of care based on best available evidence
- Easier to follow for patients
- Improved asthma control
- Decreased use oral steroids
- Fewer severe asthma exacerbations requiring ED visit or hospital care

Case # 1

- 3 year old with intermittent asthma
- Albuterol as needed once every other month during the summer
- Started preschool 2 weeks ago and now has cold with runny nose, cough. No wheezing.
- Parents call advice nurse at your office.

Case # 1

- What do you recommend to the parent?
- **New Recommendation:**
 - 7-10 day course of daily inhaled steroid.
 - PRN Albuterol

Case # 1

Children ages 0–4 years who have had three or more episodes of wheezing triggered by respiratory tract infections in their lifetime or who have had two such episodes in the past year and are asymptomatic between respiratory tract infections.

Note: absence of the word asthma.

Case # 1

- Budesonide inhalation suspension, 1 mg, twice daily for 7 days at the first sign of respiratory tract infection-associated symptoms.
- Caregivers can start intermittent ICS treatment at home without a visit to a health care provider when they have clear instructions.

Case # 1

AGES 0-4 YEARS: STEPWISE APPROACH FOR MANAGEMENT OF ASTHMA

Management of Persistent Asthma in Individuals Ages 0-4 Years						
Treatment	Intermittent Asthma	STEP 2	STEP 3	STEP 4	STEP 5	STEP 6
Preferred	PRN SABA and At the start of RTI: Add short course daily ICS▲	Daily low-dose ICS and PRN SABA	Daily medium-dose ICS and PRN SABA	Daily medium-dose ICS-LABA and PRN SABA	Daily high-dose ICS-LABA and PRN SABA	Daily high-dose ICS-LABA + oral systemic corticosteroid and PRN SABA
Alternative		Daily montelukast* or Cromolyn,* and PRN SABA		Daily medium-dose ICS + montelukast* and PRN SABA	Daily high-dose ICS + montelukast* and PRN SABA	Daily high-dose ICS + montelukast*+ oral systemic corticosteroid and PRN SABA
For children age 4 years only, see Step 3 and Step 4 on Management of Persistent Asthma in Individuals Ages 5-11 Years diagram.						
Assess Control						
<ul style="list-style-type: none"> First check adherence, inhaler technique, environmental factors,▲ and comorbid conditions. Step up if needed; reassess in 4-6 weeks Step down if possible (if asthma is well controlled for at least 3 consecutive months) Consult with asthma specialist if Step 3 or higher is required. Consider consultation at Step 2.						

Case # 2

- 3 year old with intermittent asthma
- Albuterol as needed once every other month during the summer
- Started preschool 2 weeks ago and now runny nose, cough and wheezing. Mild retractions and needing Albuterol every 4 hours for > 24 hours
- Parents call advice nurse at your office.

Case # 2

- What do you recommend to the parent?
- Start oral steroid
- Albuterol



Exacerbation management

- If needing Albuterol or ICS-formoterol more often than every 4 hours
- Retractions or wheezing not resolving or improving after rescue inhaler
- Needing rescue inhaler q 4 more than 3-4 x per day



Holger Link, MD ©

Pathology of status asthmaticus



Oral steroids

*Every child with asthma should have
prescription for a course of oral steroids
at home with instructions on when to
use*

Case # 3

- You are seeing a 14 year old child with mild persistent asthma
- At baseline rare Albuterol use on low dose inhaled steroid
- Parents learned from Instagram post that there are new asthma recommendations

Case # 3

- What do you recommend to the parent?
- They can keep going with ICS + PRN Albuterol or
- They can change to PRN Albuterol + ICS

Case # 3

AGES 12+ YEARS: STEPWISE APPROACH FOR MANAGEMENT OF ASTHMA

	Intermittent Asthma	Management of Persistent Asthma in Individuals Ages 12+ Years				
Treatment	STEP 1	STEP 2	STEP 3	STEP 4	STEP 5	STEP 6 [■]
Preferred	PRN SABA	Daily low-dose ICS and PRN SABA or PRN concomitant ICS and SABA▲	Daily and PRN combination low-dose ICS-formoterol▲	Daily and PRN combination medium-dose ICS-formoterol▲	Daily medium-high dose ICS-LABA + LAMA and PRN SABA▲	Daily high-dose ICS-LABA + oral systemic corticosteroids + PRN SABA
Alternative		Daily LTRA* and PRN SABA or Cromolyn,* or Nedocromil,* or Zileuton,* or Theophylline,* and PRN SABA	Daily medium-dose ICS and PRN SABA or Daily low-dose ICS-LABA, or daily low-dose ICS + LAMA,▲ or daily low-dose ICS + LTRA,* and PRN SABA or Daily low-dose ICS + Theophylline* or Zileuton,* and PRN SABA	Daily medium-dose ICS-LABA or daily medium-dose ICS + LAMA, and PRN SABA▲ or Daily medium-dose ICS + LTRA,* or daily medium-dose ICS + Theophylline,* or daily medium-dose ICS + Zileuton,* and PRN SABA	Daily medium-high dose ICS-LABA or daily high-dose ICS + LTRA,* and PRN SABA	

Case # 4

- 8 year old child with mild persistent asthma
- At baseline rare Albuterol use on low dose inhaled steroid
- Started school and has cough and wheezing episodes. Albuterol daily.
- Parents are calling nurse advice line

Case # 4

- What do you recommend to the parent?
- Consider stepping up therapy
- Now can consider SMART

Case # 4

	Intermittent Asthma	Management of Persistent Asthma in Individuals Ages 5–11 Years				
Treatment	STEP 1	STEP 2	STEP 3	STEP 4	STEP 5	STEP 6
Preferred	PRN SABA	Daily low-dose ICS and PRN SABA	Daily and PRN combination low-dose ICS-formoterol▲	Daily and PRN combination medium-dose ICS-formoterol▲	Daily high-dose ICS-LABA and PRN SABA	Daily high-dose ICS-LABA + oral systemic corticosteroid and PRN SABA
Alternative		Daily LTRA,* or Cromolyn,* or Nedocromil,* or Theophylline,* and PRN SABA	Daily medium-dose ICS and PRN SABA or Daily low-dose ICS-LABA, or daily low-dose ICS + LTRA,* or daily low-dose ICS + Theophylline,* and PRN SABA	Daily medium-dose ICS-LABA and PRN SABA or Daily medium-dose ICS + LTRA* or daily medium-dose ICS + Theophylline,* and PRN SABA	Daily high-dose ICS + LTRA* or daily high-dose ICS + Theophylline,* and PRN SABA	Daily high-dose ICS + LTRA* + oral systemic corticosteroid or daily high-dose ICS + Theophylline* + oral systemic corticosteroid, and PRN SABA
		Steps 2–4: Conditionally recommend the use of subcutaneous immunotherapy as an adjunct treatment to standard pharmacotherapy in individuals ≥ 5 years of age whose asthma is controlled at the initiation, build up, and maintenance phases of immunotherapy▲			Consider Omalizumab**▲	

Objectives

Review S(MART) therapy for asthma

S(MART) Therapy

Single (Maintenance And Reliever Therapy)

Step 3 and 4 care!

2025 GINA Guideline also step 1 or 2 if > 12 years of age

Rationale

- Albuterol is a muscle relaxant
- Asthma is an inflammatory disorder
- Inhaled steroids are anti-inflammatory
- It makes sense to increase anti-inflammatory therapy in addition to bronchodilation

SMART


Budesonide-formoterol dosing

		Step 3		Step 4		Step 3 or 4 max daily inhalations
Age	Dose	Maintenance	PRN	Maintenance	PRN	
≥12 years	160/4.5	1 inh BID or 1 inh qday	1 inh PRN	2 inh BID or 1 inh BID	2 inh PRN	12
4-11 years	80/4.5	1 inh daily	1 inh PRN	1 inh BID	1 inh PRN	8

Comparison Bronchodilators

Beta₂ Agonist Kinetics

Based on Anderson et al, 1994



Albuterol

- Hydrophilic
- Short duration (not stored in lipid)
- Rapid onset

Formoterol*

- Amphiphilic
- Long duration (retained by lipid)
- Rapid onset

Salmeterol*

- Lipophilic
- Long duration (retained by lipid)
- Slow onset (slow lipid diffusion to β_{2R})

Eur Respir J, 1994, 7, 569–578

(Example of action plan template for budesonide/formoterol.

A similar action plan could be constructed for other ICS/formoterol formulations, e.g. mometasone/formoterol)

My Asthma Action Plan

For Single Inhaler Maintenance
and Reliever Therapy (SMART)
with budesonide/formoterol

Name: _____ Action plan provided by: _____

Date: _____ Doctor: _____

Usual best PEF: _____ L/min Doctor's phone: _____
(If used)

Normal mode

My SMART Asthma Treatment is:

☐ budesonide/formoterol 160/4.5 (12 years or over)

☐ budesonide/formoterol 80/4.5 (4-11 years)

My Regular Treatment Every Day:

(Write in or circle the number of doses prescribed for this patient)

Take [1, 2] inhalation(s) in the morning

and [0, 1, 2] inhalation(s) in the evening, every day

Reliever

Use 1 inhalation of budesonide/formoterol
whenever needed for relief of my asthma symptoms

I should always carry my budesonide/formoterol inhaler

My asthma is stable if:

• I can take part in normal physical activity without
asthma symptoms

AND

• I do not wake up at night or in the morning
because of asthma

Other Instructions

Asthma Flare-up

If over a Period of 2-3 Days:

• My asthma symptoms are getting worse OR NOT
improving OR

• I am using more than 6 budesonide/formoterol reliever
inhalations a day (if aged 12 years and older)
or more than 4 inhalations a day (if 4-11 years)

I should:

☒ Continue to use my regular everyday treatment
PLUS 1 inhalation budesonide/formoterol whenever
needed to relieve symptoms

☐ Start a course of prednisolone

☐ Contact my doctor

Course of Prednisolone Tablets:

Take _____ mg prednisolone tablets
per day for _____ days OR

• If I need more than 12 budesonide/formoterol
inhalations (total) in any day, (or more than
8 inhalations for children 4-11 years)

I **MUST** see my doctor or go to the hospital
the same day

Asthma Emergency

Signs of an Asthma Emergency:

- Symptoms getting worse quickly
- Extreme difficulty breathing or speaking
- Little or no improvement from my
budesonide/formoterol reliever inhalations.

If I have any of the above danger signs,
I should dial _____ for an ambulance and
say I am having a severe asthma attack.

While I am waiting for the ambulance start my asthma first aid plan:

- Sit upright and stay calm
- Take 1 inhalation of budesonide/formoterol.
Wait 1-3 minutes. If there is no improvement take
another inhalation of budesonide/formoterol
(up to a maximum of 6 inhalations on a single occasion)
- If only albuterol is available, take 4 puffs
as often as needed until help arrives
- Start a course of prednisolone tablets (as directed)
while waiting for the ambulance
- Even if my symptoms appear to settle quickly,
I should see my doctor immediately after
a serious attack

Downsides

- PRN versus daily controller can be confusing to some parents
- Patients with difficulty perceiving airflow obstruction may be under or over treated
- Requires effective education of parents and patients
 - Recommend “Teach Back”

Barriers to S(MART)

- Budesonide-formoterol not FDA approved for SMART therapy
 - US packaging: ≤ 4 puffs/day max

----- INDICATIONS AND USAGE -----

SYMBICORT is a combination product containing a corticosteroid and a long-acting beta₂-adrenergic agonist indicated for:

- Treatment of asthma in patients 6 years of age and older. (1.1)
- Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. (1.2)

Important limitations:

- **Not indicated** for the relief of acute bronchospasm. (1.1, 1.2)

Barriers to S(MART)

- Patients will need supply > 30 days
- Need for additional inhaler at school
- Cost
 - Albuterol is cheaper

Case # 5

- 8 year old child with moderate to severe asthma
- Currently taking medium inhaled ICS
- Parents come to clinic as they have heard something on their Facebook group about changes in asthma therapy.
- What do you recommend to that parents?

Case # 5

- Discuss changing to ICS-formoterol for control and as reliever (SMART-therapy)

Do not use ICS-formoterol as reliever if controller is ICS-salmeterol

Case # 6

- 8 year old child with moderate to severe asthma
- Currently taking ICS-Fomoterol + PRN Albuterol
- Asthma control worsening and needing Albuterol 1-2 x per day.
- What do you recommend to the parents?

Case # 6

- Discuss replacing PRN Albuterol with ICS-Formoterol (SMART) before stepping up.